CervoMed Inc. Files 8-K Report

TL;DR

CervoMed filed an 8-K, mostly boilerplate with exhibits. Keep an eye out for details.

AI Summary

On October 29, 2024, CervoMed Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events and a Regulation FD disclosure. No specific financial figures or new material events were detailed in the provided text excerpt.

Why It Matters

This 8-K filing indicates that CervoMed Inc. is providing updated information to the SEC, which could include financial statements or other material disclosures relevant to investors.

Risk Assessment

Risk Level: low — The provided text is a standard 8-K filing notification without specific material events or financial data that would indicate immediate risk.

Key Players & Entities

• CervoMed Inc. (company) — Registrant
• 0001053691 (company) — Central Index Key
• 2024-10-29 (date) — Date of Report
• 2024-10-30 (date) — Filing Date
• 20 Park Plaza, Suite 424 Boston, Massachusetts 02116 (address) — Principal Executive Office

FAQ

Key Financial Figures

• $0.001 — on which registered Common Stock , $0.001 par value CRVO NASDAQ Capital Market

Filing Documents

• crvo20241030_8k.htm (8-K) — 31KB
• ex_739959.htm (EX-99.1) — 10KB
• logo.jpg (GRAPHIC) — 5KB
• 0001437749-24-032540.txt ( ) — 187KB
• crvo-20241029.xsd (EX-101.SCH) — 3KB
• crvo-20241029_def.xml (EX-101.DEF) — 12KB
• crvo-20241029_lab.xml (EX-101.LAB) — 15KB
• crvo-20241029_pre.xml (EX-101.PRE) — 12KB
• crvo20241030_8k_htm.xml (XML) — 3KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure Corporate Presentation Certain information concerning the business, clinical studies, development plans, financial position and related matters of CervoMed Inc. (the "Company," "we" or "us") has been made available on our website, www.cervomed.com, under the heading, "Investors – Events and Presentations." Representatives of the Company may use this presentation, in whole or in part, and possibly with non-material modifications, periodically in connection with conferences, meetings, and presentations to investors, analysts and others. The information contained in the presentation is summary information that is intended to be considered in the context of the Company's filings with the U.S. Securities and Exchange Commission ("SEC") and other public announcements that we may make, by press release or otherwise, from time to time. The Company undertakes no duty or obligation to publicly update or revise the information contained in the presentation except as required by applicable law, although the Company may do so from time to time as its management believes is warranted. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases, or through other public disclosure. The Company makes no admission or representation as to the materiality of any information in the presentation or otherwise contained in Item 7.01 of this Current Report on Form 8-K. The information in this Item 7.01 (including any information incorporated herein by reference) is furnished pursuant to Item 7.01 of Form 8-K and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of Section 18 of the Exchange Act unless we specifically incorporate it by reference in a document filed under the Exchange Act, nor shall it be deemed incorporated by reference in any filing under the Securities

01 Other Events

Item 8.01 Other Events Press Release On October 29, 2024, the Company issued a press release announcing that it will deliver an oral presentation providing detailed safety and efficacy results from its RewinD-LB Phase 2b clinical trial of neflamapimod in dementia with Lewy bodies at the eighth International Lewy Body Dementia Conference taking place on January 29-31, 2025, in Amsterdam, the Netherlands. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 99.1 Press Release, issued October 29, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 30, 2024 CervoMed Inc. By: /s/ William Elder Name: William Elder Title: Chief Financial Officer & General Counsel

View Full Filing

View this 8-K filing on SEC EDGAR